Medicare and Social Security go-broke dates pushed up due to rising health care costs, new SSA law
The go-broke date — or the date at which the programs will no longer have enough funds to pay full benefits — was pushed up to 2033 for Medicare's hospital insurance trust fund, according to the new report from the programs' trustees. Last year's report put the go-broke date at 2036.
Meanwhile, Social Security's trust funds — which cover old age and disability recipients — will be unable to pay full benefits beginning in 2034, instead of last year's estimate of 2035. After that point, Social Security would only be able to pay 81% of benefits.
The trustees say the latest findings show the urgency of needed changes to the programs, which have faced dire financial projections for decades. But making changes to the programs has long been politically unpopular, and lawmakers have repeatedly kicked Social Security and Medicare's troubling math to the next generation.
President Donald Trump and other Republicans have vowed not to make any cuts to Medicare or Social Security, even as they seek to shrink the federal government's expenditures.
'Current-law projections indicate that Medicare still faces a substantial financial shortfall that needs to be addressed with further legislation. Such legislation should be enacted sooner rather than later to minimize the impact on beneficiaries, providers, and taxpayers,' the trustees state in the report.
About 68 million people are enrolled in Medicare, the federal government's health insurance that covers those 65 and older, as well as people with severe disabilities or illnesses.
Wednesday's report shows a worsening situation for the Medicare hospital insurance trust fund compared to last year. But the forecasted go-broke date of 2033 is still later than the dates of 2031, 2028 and 2026 predicted just a few years ago.
Once the fund's reserves become depleted, Medicare would be able to cover only 89% of costs for patients' hospital visits, hospice care and nursing home stays or home health care that follow hospital visits.
The report said expenses last year for Medicare's hospital insurance trust fund came in higher than expected.
Income exceeded expenditures by nearly $29 billion last year for the hospital insurance trust fund, the report stated. Trustees expect that surplus to continue through 2027. Deficits then will follow until the fund becomes depleted in 2033.
The report states that the Social Security Social Security Fairness Act, enacted in January, which repealed the Windfall Elimination and Government Pension Offset provisions of the Social Security Act and increased Social Security benefit levels for some workers, had an impact on the depletion date of SSA's trust funds.
Social Security benefits were last reformed roughly 40 years ago, when the federal government raised the eligibility age for the program from 65 to 67. The eligibility age has never changed for Medicare, with people eligible for the medical coverage when they turn 65.
Nancy Altman, president of Social Security Works, an advocacy group for the popular public benefit program said in a statement that 'there are two options for action: Bringing more money into Social Security, or reducing benefits. Any politician who doesn't support increasing Social Security's revenue is, by default, supporting benefit cuts.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
New malaria drug for babies offers hope to health workers in Uganda
Uganda New Malaria Drug KAMPALA, Uganda (AP) — Alice Nekesa did not know she was infected with malaria-causing parasites until it was too late. She was in the fourth month of pregnancy last year when she started bleeding, a miscarriage later attributed to untreated malaria in her. The Ugandan farmer said recently that she regretted the loss of what would have been her second child 'because I didn't discover malaria and treat it early.' Variations of such cases are commonly reported by Ugandan health workers who witness stillbirths or feverish babies that die within days from undiagnosed malaria. The deaths are part of a wider death toll tied to the mosquito-borne disease, the deadliest across Africa, but one easily treated in adults who seek timely medical care. Until recently, a major gap in malaria treatment was how to care for newborns and infants infected with malaria who weren't strong enough to receive regular medication. That changed last month when Swiss medical regulators approved medicine from the Basel-based pharmaceutical company Novartis for babies weighing between 2 and 5 kilograms (nearly 4½ to 11 pounds). Swissmedic said the treatment, a sweet-tasting tablet that disperses into a syrup when dropped into water, was approved in coordination with the World Health Organization under a fast-track authorization process to help developing countries access much-needed treatment. Africa's 1.5 billion people accounted for 95% of an estimated 597,000 malaria deaths worldwide in 2023, according to the WHO. More than three-quarters of those deaths were among children. In Uganda, an east African country of 45 million people, there were 12.6 million malaria cases and nearly 16,000 deaths in 2023. Many were children younger than 5 and pregnant women, according to WHO. Nigeria, Congo and Uganda — in that order — are the African countries most burdened by malaria, a parasitic disease transmitted to humans through the bites of infected mosquitoes that thrive and breed in stagnant water. The drug approved by Swiss authorities, known as Coartem Baby in some countries and Riamet Baby in others, is a combination of two antimalarials. It is a lower dose version of a tablet previously approved for other age groups, including for older children. Before Coartem Baby, antimalarial drugs designed for older children were administered to small infants with careful adjustments to avoid overdose or toxicity. Ugandan authorities, who have been working to update clinical guidelines for treating malaria, say the new drug will be rolled out as soon as possible. It is not yet available in public hospitals. The development of Coartem Baby has given hope to many, with local health workers and others saying the medicine will save the lives of many infants. Ronald Serufusa, the top malaria official for the district of Wakiso, which shares a border with the Ugandan capital of Kampala, said he believes Coartem Baby will be available 'very, very soon' and that one priority is sensitizing the people adhering to treatment. Some private pharmacies already have access to Coartem Baby, 'flavored with orange or mango' to make it palatable for infants, he said. During the so-called malaria season, which coincides with rainy periods twice a year, long lines of sick patients grow outside government-run health centers across Uganda. Many are often women with babies strapped to their backs. Health workers now are trained to understand that 'malaria can be implicated among newborns,' even when other dangerous conditions like sepsis are present, Serufusa said. 'If they don't expand their investigations to also suspect malaria, then it goes unnoticed,' he said, speaking of health workers treating babies. The Malaria Consortium, a global nonprofit based in London, in a statement described the approval of Coartem Baby as 'a major leap forward for saving the lives of young children in countries affected by malaria.' In addition to Uganda, the drug will be rolled out in Burkina Faso, Côte d'Ivoire, Kenya, Malawi, Mozambique, Nigeria, and Tanzania, the group said. Jane Nabakooza, a pediatrician with Uganda's malaria control program, said she expects the government will make Coartem Baby available to patients free of charge, even after losing funding when the U.S. shrank its foreign aid program earlier this year. Some malaria funding from outside sources, including the Global Fund to Fight AIDS, Malaria and Tuberculosis, remains available for programs such as indoor spraying to kill mosquitoes that spread the malaria-causing parasite. Because of funding shortages, 'we are focusing on those that are actually prone to severe forms of malaria and malaria deaths, and these are children under 5 years,' she said. ___ The Associated Press receives financial support for global health and development coverage in Africa from the Gates Foundation. The AP is solely responsible for all content. Find AP's standards for working with philanthropies, a list of supporters and funded coverage areas at Solve the daily Crossword
Associated Press
21 minutes ago
- Associated Press
New malaria drug for babies offers hope to health workers in Uganda
KAMPALA, Uganda (AP) — Alice Nekesa did not know she was infected with malaria-causing parasites until it was too late. She was in the fourth month of pregnancy last year when she started bleeding, a miscarriage later attributed to untreated malaria in her. The Ugandan farmer said recently that she regretted the loss of what would have been her second child 'because I didn't discover malaria and treat it early.' Variations of such cases are commonly reported by Ugandan health workers who witness stillbirths or feverish babies that die within days from undiagnosed malaria. The deaths are part of a wider death toll tied to the mosquito-borne disease, the deadliest across Africa, but one easily treated in adults who seek timely medical care. Until recently, a major gap in malaria treatment was how to care for newborns and infants infected with malaria who weren't strong enough to receive regular medication. That changed last month when Swiss medical regulators approved medicine from the Basel-based pharmaceutical company Novartis for babies weighing between 2 and 5 kilograms (nearly 4½ to 11 pounds). Swissmedic said the treatment, a sweet-tasting tablet that disperses into a syrup when dropped into water, was approved in coordination with the World Health Organization under a fast-track authorization process to help developing countries access much-needed treatment. Africa's 1.5 billion people accounted for 95% of an estimated 597,000 malaria deaths worldwide in 2023, according to the WHO. More than three-quarters of those deaths were among children. In Uganda, an east African country of 45 million people, there were 12.6 million malaria cases and nearly 16,000 deaths in 2023. Many were children younger than 5 and pregnant women, according to WHO. Nigeria, Congo and Uganda — in that order — are the African countries most burdened by malaria, a parasitic disease transmitted to humans through the bites of infected mosquitoes that thrive and breed in stagnant water. The drug approved by Swiss authorities, known as Coartem Baby in some countries and Riamet Baby in others, is a combination of two antimalarials. It is a lower dose version of a tablet previously approved for other age groups, including for older children. Before Coartem Baby, antimalarial drugs designed for older children were administered to small infants with careful adjustments to avoid overdose or toxicity. Ugandan authorities, who have been working to update clinical guidelines for treating malaria, say the new drug will be rolled out as soon as possible. It is not yet available in public hospitals. The development of Coartem Baby has given hope to many, with local health workers and others saying the medicine will save the lives of many infants. Ronald Serufusa, the top malaria official for the district of Wakiso, which shares a border with the Ugandan capital of Kampala, said he believes Coartem Baby will be available 'very, very soon' and that one priority is sensitizing the people adhering to treatment. Some private pharmacies already have access to Coartem Baby, 'flavored with orange or mango' to make it palatable for infants, he said. During the so-called malaria season, which coincides with rainy periods twice a year, long lines of sick patients grow outside government-run health centers across Uganda. Many are often women with babies strapped to their backs. Health workers now are trained to understand that 'malaria can be implicated among newborns,' even when other dangerous conditions like sepsis are present, Serufusa said. 'If they don't expand their investigations to also suspect malaria, then it goes unnoticed,' he said, speaking of health workers treating babies. The Malaria Consortium, a global nonprofit based in London, in a statement described the approval of Coartem Baby as 'a major leap forward for saving the lives of young children in countries affected by malaria.' In addition to Uganda, the drug will be rolled out in Burkina Faso, Côte d'Ivoire, Kenya, Malawi, Mozambique, Nigeria, and Tanzania, the group said. Jane Nabakooza, a pediatrician with Uganda's malaria control program, said she expects the government will make Coartem Baby available to patients free of charge, even after losing funding when the U.S. shrank its foreign aid program earlier this year. Some malaria funding from outside sources, including the Global Fund to Fight AIDS, Malaria and Tuberculosis, remains available for programs such as indoor spraying to kill mosquitoes that spread the malaria-causing parasite. Because of funding shortages, 'we are focusing on those that are actually prone to severe forms of malaria and malaria deaths, and these are children under 5 years,' she said. ___ The Associated Press receives financial support for global health and development coverage in Africa from the Gates Foundation. The AP is solely responsible for all content. Find AP's standards for working with philanthropies, a list of supporters and funded coverage areas at
Bloomberg
21 minutes ago
- Bloomberg
World's Two Biggest Miners Meet With Trump Over Copper Project
The chief executive officers of the world's two biggest mining companies met President Donald Trump to discuss a copper project that could supply the US with a quarter of its demand for decades to come. Rio Tinto Group's Jakob Stausholm; his incoming replacement, Simon Trott; and counterpart at BHP Group, Mike Henry, met the US leader to discuss the Resolution project in Arizona, according to a Linkedin post by Stausholm.
